gametocyte specific factor 1Genealiases: Cue110 · FAM112B
Q-omics provides the consensus-scored GTSF1 profile across patient tissues and cancer cell-line models. GTSF1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GTSF1 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, GTSF1 RNA expression shows 13,493 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, HNSC, and TGCT as cancer lineages where GTSF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTSF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTSF1 survival associations across molecular data types. GTSF1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTSF1 RNA expression–survival associations across cancer types. High GTSF1 expression shows unfavorable associations in LGG, but favorable associations in SKCM, ESCA, HNSC, SCLC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GTSF1 RNA expression.
This table summarizes GTSF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GTSF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTSF1 shows lower tumor expression in COAD and higher tumor expression in HNSC, KIRP, KIRC, LIHC and BRCA. The HNSC box plot shows higher GTSF1 RNA expression in tumor versus normal tissue (log2 FC = +1.436, t-test p < 0.001).
This table shows molecular features associated with GTSF1 in patient tissues and cancer cell lines. In patient samples, GTSF1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GTSF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUSC.
